In Brief: Neopath AutoPap
This article was originally published in The Gray Sheet
Neopath AutoPap: Firm submits prospective clinical data requested by FDA in support of its pending premarket approval application supplement for use of the AutoPap as a primary Pap smear screener. At a September 1996 meeting, FDA's Hematology and Pathology Devices Panel recommended against approval of the PMA supplement and called for additional prospective studies comparing conventional cytologist slide review to AutoPap review ("The Gray Sheet" Oct. 7, 1996, p. 8). The automated Pap smear analysis system was approved in September 1995 for quality control rescreening of previously screened Pap smear slides...
You may also be interested in...
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.